Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Atara Biotherapeutics (ATRA) Operating Expenses (2022 - 2026)

Atara Biotherapeutics filings provide 5 years of Operating Expenses readings, the most recent being $3.9 million for Q1 2026.

  • On a quarterly basis, Operating Expenses fell 93.45% to $3.9 million in Q1 2026 year-over-year; TTM through Mar 2026 was $29.4 million, a 86.18% decrease, with the full-year FY2025 number at $84.9 million, down 60.02% from a year prior.
  • Operating Expenses hit $3.9 million in Q1 2026 for Atara Biotherapeutics, down from $4.2 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $95.5 million in Q1 2022 to a low of $3.9 million in Q1 2026.
  • Median Operating Expenses over the past 5 years was $61.9 million (2024), compared with a mean of $54.7 million.
  • Biggest five-year swings in Operating Expenses: increased 1.27% in 2025 and later plummeted 93.45% in 2026.
  • Atara Biotherapeutics' Operating Expenses stood at $75.8 million in 2022, then dropped by 15.24% to $64.2 million in 2023, then dropped by 29.99% to $45.0 million in 2024, then crashed by 90.75% to $4.2 million in 2025, then decreased by 6.57% to $3.9 million in 2026.
  • The last three reported values for Operating Expenses were $3.9 million (Q1 2026), $4.2 million (Q4 2025), and $7.0 million (Q3 2025) per Business Quant data.